MMS® can provide tailored medicines optimisation programmes that support clinicians to provide improved healthcare for their patients. We can work alongside you to provide improved patient outcomes as well as offer significant savings for you and the NHS.
We can implement a fully trained clinical pharmacist to work with patients face to face or manage your medicines optimisation remotely. Our pharmacist can highlight changes that may need to be made with the patient’s therapy and work to provide a solution that is clinically appropriate as well as cost effective.
A MMS® Practice Pharmacist can offer significant savings; with an average of £500,000 saved per year per population of 100,000.
MMS® Practice Pharmacists have been proven to alleviate the GP workload by undertaking medicines related responsibilities. Our pharmacists supported patients to improve compliance and reduce medicines wastage as well as medicines associated harm. Qualitative outcomes were also coupled with a significant reduction in prescribing spend.
MMS® can provide a series of Therapy Optimisation Programmes that can maximise QIPP potential. These programmes are designed to optimise patient care whist releasing budgetary savings in line with national QIPP challenges.
Our range of therapy optimisation programmes can be offered with flexible models in both delivery and funding. These include part or full sponsorship, in which case clinical reviews may be implemented with no cost implications to your GP Practice, CCG or GP Federation.
An ‘invest to save’ model including options for risk share would typically deliver in excess of a five-fold return on investment. On average our suite of optimisation programmes generate a deliverable saving projection of £500,000 per 100,000 population.
Our programmes are highly customisable and can be tailored to suit your requirements. Please contact MMS® for further information and to speak to a member of our senior clinical team.
Medicines Optimisation Programmes
MMS® have designed over 20 programmes to support NHS QIPP and medicines optimisation priorities
across a broad range of therapy areas & conditions, including; respiratory, malnutrition, osteoporosis, dermatology, inflammatory bowel disease, diabetes, stroke prevention and other cardiovascular conditions.
Key features & benefits include;
Optimise therapeutic management of patients
Promote alignment to national & local guidance
Maximise opportunities to reduce cost and medicines waste
Reduce medicines related adverse effects and admissions
Case Example: Model 1 QIPP Programme
MMS® Worked in collaboration with commissioning groups and pharma industry to meet challenges and provide significant outcomes across a CCG in the North East of England.
Popular MMS® Programmes
Optimise emollient usage and review
Ensure cost effective prescribing of emollients
Reduce flare up related GP and Hospital appointments
Oral Nutritional Supplements
Ensure appropriate prescribing in accordance with local pathways
Incorporate care home reviews and ONS/MUST training support
Maximise prescribing efficiencies in management of malnutrition
To improve adherence to national UKMEC guidance and local prescribing formulary
Optimise prescribing efficiencies
Reduce likelihood or drug related adverse effects
Type II Diabetes
Optimise therapy to achieve optimum glycaemic control in Type II Diabetes
Review therapy in like with NICE guidance NG28
Maximise QIPP and QOF outcomes
Asthma & COPD
Review and optimise prescribing in line with updated guidance
Reduce fluticasone burden and associated risks
Optimise therapeutic management of Asthma and COPD
Care Home Support
Polypharmacy review - STOPP/START
Reduce wastage of medicines
Reduce risk and unnecessary hospital admissions
Blood Glucose Testing
Review and rationalise SMBG in Type II Diabetes
Facilitate transition to formulary choice test strips
Appropriate and cost effective prescribing
Atrial Fibrillation & Stroke Prevention
Risk stratify and identify patients at risk of nvAF related stroke
Optimise therapeutic management to reduce incidence of avoidable strokes
Review to highlight QIPP opportunities within DOAC prescribing
Opioid Pain Relief
Review prescribing in line with CQC and NHS England recommendations
Review prescribing in line with the WHO Pain Ladder
Review palliative care QOF indicators maximising outcomes for patients and the practice
Incorporating Alzheimer's, Parkinson's and Schizophrenia
Review for appropriate therapeutic monitoring and discharge reconcilliation
Optimise prescribing efficiencies by prescribing with the lowest acquisition cost
Commissioning for quality
MMS® can provide skilled clinical pharmacists to undertake patient centred clinical review projects to improve patient health outcomes in line with CCG objectives and NHS Right Care strategies.
MMS® have experience in delivering in the following areas:
- Care Home Reviews
- Stroke Prevention
- Domiciliary and Frailty Reviews
- Reducing risk of hospital admission / Virtual Clinics
- Embedding GP Practice Pharmacists
Please contact MMS for more information on our Medicines Optimisation Programmes or to speak to one of our Senior Clinical Team
MMS Frail & Elderly Prescribing reviews – Maximising Quality Prescribing
Polypharmacy within the frail & elderly is an emerging problem and is associated with increased risks:
- Patients on 10 or more medicines are over 3 times more likely to be admitted to hospital
- Between 30-50% of prescribed medicines are not taken as recommended
- Adverse Drug Reactions (ADRs) account for 6.5% of hospital admissions, of which 70% are avoidable
- At least 6% of emergency admissions are caused by medicines
Department of Health & Social Care research has estimated that primary care medication errors leading to hospital admissions cause 627 deaths and cost the NHS £83.7m a year. in total across the NHS it is estimated that medication errors caused 712 deaths a year, costing £98.5m.
MMS have developed service models to support NHS organisations to review the most vulnerable and improve outcomes for the frail and care home populations.